Brief: Dyadic - Feb. 16 Presentation Had Discussion Of Plan To Initiate Potential Phase I Clinical Study Related To Co's Recombinant Sars-Cov-2 Rbd Antigen
18/02/2021 14:33
Feb 18 (Reuters) - Dyadic International Inc DYAI.O :
* DYADIC - FEB. 16 PRESENTATION HAD DISCUSSION OF PLAN TO
INITIATE
POTENTIAL PHASE I CLINICAL STUDY RELATED TO CO'S RECOMBINANT
SARS-COV-2 RBD ANTIGEN
* DYADIC INTERNATIONAL INC - ON FEB 16, CEO ALSO DISCUSSED
CO'S
INTENTION TO DEVELOP POTENTIAL SARS-COV-2 VACCINE PRODUCT
CANDIDATE(S)
Source text for Eikon: [ID: https://bit.ly/3pFtbbH]
Further company coverage: DYAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development